

# CITATION REPORT

List of articles citing

**Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study**

**DOI: 10.1016/j.clinthera.2008.08.006**  
**Clinical Therapeutics, 2008, 30, 1448-60.**

**Source:** <https://exaly.com/paper-pdf/44103635/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
307	Efficacy and safety of incretin based therapies: clinical trial data. <b>2009</b> , 49 Suppl 1, S30-40		54
306	Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes. <b>2009</b> , 1, 1103-1119		1
305	Alogliptin: a new addition to the class of DPP-4 inhibitors. <b>2009</b> , Volume 2, 117-126		29
304	Role and development of GLP-1 receptor agonists in the management of diabetes. <b>2009</b> , Volume 2, 37-49		12
303	Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. <b>2009</b> , 49 Suppl 1, S16-29		101
302	Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. <b>2009</b> , 76 Suppl 5, S28-38		48
301	Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. <b>2009</b> , 160, 909-17		106
300	Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies. <b>2009</b> , 121, 16-25		34
299	Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge. <b>2009</b> , 37, 7-21		2
298	Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. <b>2009</b> , 121, 5-15		23
297	Beyond glycemic control: treating the entire type 2 diabetes disorder. <b>2009</b> , 121, 68-81		19
296	The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. <b>2009</b> , 29, 55S-67S		15
295	Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. <b>2009</b> , 9, 55-68; discussion 69-71		54
294	Exercise therapy in type 2 diabetes. <b>2009</b> , 46, 263-78		82
293	Exenatide once weekly for the treatment of type 2 diabetes. <b>2009</b> , 18, 359-67		35
292	Incretin therapies: effects beyond glycemic control. <b>2009</b> , 20 Suppl 2, S319-28		16
291	Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. <b>2009</b> , 20 Suppl 2, S309-18		20

290	Unraveling the science of incretin biology. <b>2009</b> , 20 Suppl 2, S303-8	40
289	Unraveling the science of incretin biology. <b>2009</b> , 122, S3-S10	111
288	Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. <b>2009</b> , 122, S11-24	41
287	Incretin therapies: effects beyond glycaemic control. <b>2009</b> , 122, S25-36	27
286	Pharmacotherapy of hyperglycemia. <b>2009</b> , 10, 2415-32	11
285	Incretin-Based Therapies in Patients with Type 2 Diabetes. <b>2010</b> , 5, 75-85	
284	Managing type 2 diabetes in the primary care setting: beyond glucocentricity. <b>2010</b> , 340, 133-43	4
283	Weight management in type 2 diabetes mellitus. <b>2010</b> , 77, 533-48	12
282	Glycaemic control in type 2 diabetes: targets and new therapies. <b>2010</b> , 125, 328-61	130
281	Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. <b>2010</b> , 30, 609-24	43
280	The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. <b>2010</b> , 9, 32	54
279	Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. <b>2010</b> , 9, 6	107
278	Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. <b>2010</b> , 9, 76	94
277	Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?. <b>2010</b> , 64, 791-801	23
276	The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. <b>2010</b> , 64, 1402-14	31
275	Liraglutide: effects beyond glycaemic control in diabetes treatment. <b>2010</b> , 64, 28-34	11
274	Emerging treatment options for type 2 diabetes. <b>2010</b> , 70, 631-44	42
273	Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. <b>2010</b> , 12, 267-87	63

272	A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. <b>2010</b> , 12, 1058-65	56
271	In support of an early polypharmacy approach to the treatment of type 2 diabetes. <b>2010</b> , 12, 929-40	20
270	Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects. <b>2010</b> , 27, 1168-73	19
269	Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. <b>2010</b> , 6, 401-11	19
268	Emerging role of GLP-1 receptor agonists in the treatment of obesity. <b>2010</b> , Volume 3, 263-273	8
267	Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. <b>2010</b> , 6, 541-8	80
266	Clinical utility of fixed combinations of sitagliptin&ndash;metformin in treatment of type 2 diabetes. <b>2010</b> , Volume 3, 363-372	4
265	Exenatide Use in the Management of Type 2 Diabetes Mellitus. <b>2010</b> , 3, 2554-2567	11
264	Current developments in the treatment of diabetes: the incretin therapies. <b>2010</b> , 10, 21-30	1
263	Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. <b>2010</b> , 23, 334-9	153
262	A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. <b>2010</b> , 86, 44-57	96
261	Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. <b>2010</b> , 59, 1063-73	228
260	The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. <b>2010</b> , 12, 11-24	29
259	Effectiveness of exenatide in Asian Indians in a clinical care setting. <b>2010</b> , 12, 613-8	4
258	Understanding GLP-1 analogs and enhancing patients success. <b>2010</b> , 36 Suppl 3, 44S-72S; quiz 73S-74S	14
257	Can therapies that target the incretin system improve our ability to treat type 2 diabetes?. <b>2010</b> , 102, 511-23	5
256	Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes. <b>2010</b> , 122, 7-15	90
255	Managing type 2 diabetes: balancing HbA1c and body weight. <b>2010</b> , 122, 106-17	21

254	Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus. <b>2010</b> , 33, 87-100	19
253	Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity. <b>2010</b> , 36, 293-8	23
252	Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. <b>2010</b> , 123, S19-27	52
251	Dietary effects on incretin hormone secretion. <b>2010</b> , 84, 81-110	41
250	Exenatide versus glibenclamide in patients with diabetes. <b>2010</b> , 12, 233-40	97
249	Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. <b>2011</b> , 27, 531-40	4
248	Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. <b>2011</b> , 34, 69-77	18
247	Pramlintide and the treatment of diabetes: a review of the data since its introduction. <b>2011</b> , 12, 1439-51	64
246	Tailoring treatment for type 2 diabetes: Uncovering the HOW and NOW of GLP-1 receptor agonist therapy. <b>2011</b> , 3, 217-236	1
245	Type 2 Diabetes in Adults. <b>2011</b> , 77-137	3
244	Incretin-based therapies and their future in Type 2 diabetes mellitus. <b>2011</b> , 8, 143-152	1
243	Glucagon-like peptide analogues for type 2 diabetes mellitus. <b>2011</b> , CD006423	101
242	Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. <b>2011</b> , 124, S3-18	220
241	Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?. <b>2011</b> , 124, S19-34	54
240	Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. <b>2011</b> , 37, 477-88	38
239	GLP-1 receptor agonists today. <b>2011</b> , 93, 317-27	17
238	Advances in the treatment of type 2 diabetes mellitus. <b>2011</b> , 18, 117-52	112
237	The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors. <b>2011</b> , 20, 476-81	25

236	Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. <b>2011</b> , 154, 103-12		405
235	Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. <b>2011</b> , 13, 99-117		30
234	Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. <b>2011</b> , 13, 302-12		104
233	Update on incretin hormones. <b>2011</b> , 1243, E55-74		88
232	Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 393-407	3.5	24
231	Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 408-24	3.5	22
230	Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 511-27	3.5	70
229	Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 528-76	3.5	39
228	Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 1868-82	3.5	21
227	Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. <b>2011</b> , 45, 850-60		45
226	Lixisenatide for type 2 diabetes mellitus. <b>2011</b> , 20, 549-57		64
225	The Incretin System and Cardiovascular Risk: Effects of Incretin-Targeted Therapies. <b>2011</b> , 5, 62-69		1
224	Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. <b>2011</b> , 2, 101-21		76
223	Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. <b>2011</b> , 10, 22		124
222	The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. <b>2011</b> , 27, 528-42		75
221	Potential use of exenatide for the treatment of obesity. <b>2011</b> , 20, 1717-22		9
220	Liraglutide for type 2 diabetes mellitus. <b>2011</b> , 11, 951-9		3
219	The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. <b>2011</b> , 123, 189-201		25

218	Glycemic control impact on body weight potential to reduce cardiovascular risk: glucagon-like peptide 1 agonists. <b>2011</b> , 34 Suppl 2, S272-5	3
217	GLP-1 receptor agonists and HBA1c target of . <b>2011</b> , 27, 1519-28	37
216	Predicting response to incretin-based therapy. <b>2011</b> , 11	
215	Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. <b>2011</b> , 2011, 215764	85
214	The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus. <b>2011</b> , 4, 13-24	2
213	Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview. <b>2011</b> , 24, 26-35	5
212	Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials. <b>2011</b> , 1, 327-343	1
211	Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence. <b>2012</b> , 30, 3-12	24
210	Current updates in the medical management of obesity. <b>2012</b> , 6, 117-28	17
209	Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. <b>2012</b> , 3, 185-201	4
208	Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. <b>2012</b> , 124, 21-32	33
207	GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. <b>2012</b> , 7, 214-28	39
206	The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: a European expert recommendation. <b>2012</b> , 6, 665-73	11
205	Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. <b>2012</b> , 35, 252-8	261
204	Safety and tolerability of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. <b>2012</b> , 12, 6-16	1
203	Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). <b>2012</b> , 35, 1225-31	183
202	Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus. <b>2012</b> , 69, 1044-8	4
201	Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. <b>2012</b> , 2012, 230624	28

200	Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective. <b>2012</b> , 2012, 381713	36
199	Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. <b>2012</b> , 2012, 672658	61
198	Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. <b>2012</b> , 29, 1260-7	73
197	Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. <b>2012</b> , 344, d7771	575
196	The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. <b>2012</b> , 14, 561-7	52
195	Targeting the glucagon receptor family for diabetes and obesity therapy. <b>2012</b> , 135, 247-78	109
194	Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models. <b>2012</b> , 33, 1013-22	8
193	Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes. <b>2012</b> , 36, 9-14	3
192	Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. <b>2012</b> , 66, 1147-57	12
191	A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. <b>2012</b> , 13, 1451-67	21
190	Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants. <b>2012</b> , 32, 1-14	27
189	[Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide]. <b>2012</b> , 139, 572-8	3
188	Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes. <b>2012</b> , 7, 15-26	6
187	Glucagon-like peptide-1 and its cardiovascular effects. <b>2012</b> , 14, 422-8	12
186	Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. <b>2012</b> , 18, 227-37	11
185	The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials. <b>2012</b> , 15, 1-30	20
184	Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States. <b>2012</b> , 18, 700-11	5
183	Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. <b>2012</b> , 5, 29-41	33



182	The effect of glucagon-like peptide 1 on cardiovascular risk. <b>2012</b> , 9, 209-22		117
181	Drug-induced hypoglycaemia in type 2 diabetes. <b>2012</b> , 11, 597-614		39
180	[Cardiovascular effects of incretin-based therapies]. <b>2012</b> , 37, 287-93		0
179	Effects of incretins on blood pressure: a promising therapy for type 2 diabetes mellitus with hypertension. <b>2012</b> , 4, 22-9		7
178	Using albumin to improve the therapeutic properties of diabetes treatments. <b>2012</b> , 14, 121-9		8
177	Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. <b>2012</b> , 109, 1681-5		55
176	Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. <i>Clinical Therapeutics</i> , <b>2012</b> , 34, 1247-1258.e22	3.5	200
175	Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. <b>2012</b> , 37, 510-24		35
174	The role of the nurse practitioner in the diagnosis and early management of type 2 diabetes. <b>2012</b> , 24 Suppl 1, 225-33		5
173	The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. <b>2012</b> , 59, 464-71		96
172	The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review. <b>2012</b> , 14, 387-98		13
171	Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. <b>2012</b> , 14, 546-54		113
170	Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. <b>2012</b> , 4, 8		13
169	Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus. <b>2012</b> , 14, 60-9		20
168	Current issues in GLP-1 receptor agonist therapy for type 2 diabetes. <b>2012</b> , 18 Suppl 3, 6-26; quiz 27-8		6
167	Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?. <b>2013</b> , 56, 1878-83		34
166	Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes. <b>2013</b> , 13, 319-28		2
165	Complementing insulin therapy to achieve glycemic control. <b>2013</b> , 30, 557-76		28

164	Update Hypertonie. <b>2013</b> , 9, 373-379		
163	Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?. <b>2013</b> , 30, 289-99		23
162	Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 µg. <i>Clinical Therapeutics</i> , <b>2013</b> , 35, 795-807	3.5	34
161	Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. <b>2013</b> , 39, 485-96		59
160	Incretin-based therapies: focus on effects beyond glycemic control alone. <b>2013</b> , 4, 221-38		12
159	The Metabolic Syndrome. <b>2013</b> ,		6
158	GLP-1 receptor agonists: effects on cardiovascular risk reduction. <b>2013</b> , 31, 238-49		56
157	Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data. <b>2013</b> , 8, 105-121		8
156	GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. <b>2013</b> , 15, 15-27		193
155	Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes. <b>2013</b> , 100, 1-10		31
154	Successful Primary Care Management of Type II DiabetesContents. <b>2013</b> , 4-111		
153	New incretin hormonal therapies in humans relevant to diabetic cats. <b>2013</b> , 43, 417-33		4
152	Review article: a comparison of glucagon-like peptides 1 and 2. <b>2013</b> , 37, 18-36		75
151	A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. <b>2013</b> , 15, 213-23		43
150	Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. <b>2013</b> , 15, 14-33		251
149	Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013. <b>2013</b> , 5, 241-53		8
148	Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. <b>2013</b> , 47, 490-505		28
147	The Role of Glucagon-like Receptor-1 Agonists in the Metabolic Syndrome. <b>2013</b> , 165-183		

146	Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. <b>2013</b> , 15, 737-49	139
145	Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. <b>2013</b> , 15, 593-606	38
144	Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes. <b>2013</b> , 29, 1617-26	11
143	Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice. <b>2013</b> , 19, 718-28	7
142	Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach. <b>2013</b> , 125, 112-26	9
141	Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. <b>2013</b> , 3,	207
140	Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects. <b>2013</b> , 20, 384-93	4
139	Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol. <b>2013</b> , 20, 638-53	8
138	Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature. <b>2013</b> , 8, 247-259	18
137	Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension. <b>2013</b> , 21, 8-24	155
136	The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. <b>2013</b> , 36, 498-504	80
135	Practical Use of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Primary Care. <b>2013</b> , 31, 148-157	32
134	Evolution of Exenatide as a Diabetes Therapeutic. <b>2013</b> , 9, 161-193	2
133	Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. <b>2013</b> , 6, 877-95	43
132	Evolution of exenatide as a diabetes therapeutic. <b>2013</b> , 9, 161-93	45
131	Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. <b>2014</b> , 9, e97554	103
130	Treating the elderly diabetic patient: special considerations. <b>2014</b> , 7, 391-400	6
129	Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. <b>2014</b> , 7, 15-24	28

128	Assessment of pancreatic $\beta$ cell function: review of methods and clinical applications. <b>2014</b> , 10, 2-42	119
127	Managing loss of glycemic control in middle-aged patients with diabetes: the role of GLP-1 receptor agonists in combination-therapy regimens. <b>2014</b> , 114, S14-21	0
126	Managing recent-onset diabetes: choosing durable, well-tolerated therapies and understanding the role of incretin-based therapies. <b>2014</b> , 114, S6-13	1
125	Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). <b>2014</b> , 31, 176-84	93
124	Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. <b>2014</b> , 16, 900-9	112
123	Regulation of glucose homeostasis by GLP-1. <b>2014</b> , 121, 23-65	127
122	Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists. <b>2014</b> , 32, 32-43	5
121	Evidence-based practice use of incretin-based therapy in the natural history of diabetes. <b>2014</b> , 126, 66-84	9
120	Management of type 2 diabetes mellitus in self-motivated patients: optimized diet, exercise, and medication for weight loss and cardiometabolic fitness. <b>2014</b> , 42, 49-59	4
119	The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. <b>2014</b> , 16, 9-21	87
118	Second-line agents for glycemic control for type 2 diabetes: are newer agents better?. <b>2014</b> , 37, 1338-45	50
117	Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus. <b>2014</b> , 74, 325-51	37
116	Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. <b>2014</b> , 27, 130-9	94
115	Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). <b>2014</b> , 16, 748-56	50
114	The potential for renoprotection with incretin-based drugs. <b>2014</b> , 86, 701-11	77
113	Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors'expert forum. <b>2014</b> , 37, 2647-59	48
112	[Effects of GLP-1 receptor agonists on carbohydrate metabolism control]. <b>2014</b> , 143 Suppl 2, 18-22	
111	[Safety and tolerability of GLP-1 receptor agonists]. <b>2014</b> , 143 Suppl 2, 35-40	1

110	GLP-1R activation for the treatment of stroke: updating and future perspectives. <b>2014</b> , 15, 233-42	17
109	Effects of GLP-1 on appetite and weight. <b>2014</b> , 15, 181-7	106
108	Efficacy of liraglutide in a real-life cohort. <b>2014</b> , 5, 193-206	15
107	Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes. <b>2014</b> , 40, 284-91	11
106	Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. <b>2014</b> , 221, T1-16	141
105	Two novel solvent system compositions for protected synthetic peptide purification by centrifugal partition chromatography. <b>2014</b> , 1337, 155-61	4
104	New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering?. <b>2014</b> , 23, 997-1008	8
103	The effect of chronic twice daily exenatide treatment on $\beta$ cell function in new onset type 2 diabetes. <b>2014</b> , 80, 545-53	18
102	Exenatide enhances INS-1 rat pancreatic $\beta$ cell mass by increasing the protein levels of adiponectin and reducing the levels of C-reactive protein. <b>2014</b> , 10, 2447-52	3
101	Implications of incretin-based therapies on cardiovascular disease. <b>2015</b> , 69, 531-49	10
100	Effects of Glucagon-Like Peptide-1 Receptor Agonists on $\beta$ Cell Function in Patients with Type 2 Diabetes. <b>2015</b> , 07,	
99	Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists. <b>2015</b> , 06,	1
98	GLP-1 based therapeutics: simultaneously combating T2DM and obesity. <b>2015</b> , 9, 92	67
97	Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. <b>2015</b> , 172, 721-36	20
96	Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). <b>2015</b> , 45, 269-78	108
95	Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. <b>2015</b> , 385, 2057-66	151
94	Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. <b>2015</b> , 6, 109-34	33
93	Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. <b>2015</b> , 17, 35-42	54

92	Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. <i>Clinical Therapeutics</i> , <b>2015</b> , 37, 225-241.e8	3.5	115
91	Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. <b>2015</b> , 6, 3-18		33
90	Pharmacologic treatment of type 2 diabetes: injectable medications. <b>2015</b> , 49, 700-14		19
89	Incretin-based therapies. <b>2015</b> , 726-744		
88	Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy. <b>2015</b> , 127, 827-41		10
87	Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies. <b>2015</b> , 127, 480-93		5
86	Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective. <b>2015</b> , 17, 335-42		9
85	A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes. <b>2016</b> , 37, 834-42		5
84	Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists. <b>2016</b> , 31, 258-74		29
83	GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen. <b>2016</b> , 36, 893-905		10
82	The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. <b>2016</b> , 82, 301-14		19
81	Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. <b>2016</b> , 16, 44		11
80	NUEVOS FARMACOS EN DIABETES MELLITUS. <b>2016</b> , 27, 235-256		2
79	Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon. <b>2016</b> , 326, 279-341		11
78	Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 µg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis. <b>2016</b> , 8, 866-876		4
77	Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. <b>2016</b> , 68, 954-1013		171
76	Role of glucagon-like peptide 1 receptor agonists in management of obesity. <b>2016</b> , 73, 1493-507		30
75	Molecular regulation of insulin granule biogenesis and exocytosis. <b>2016</b> , 473, 2737-56		14

74	A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. <b>2016</b> , 8, 341ra76	77
73	Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis. <b>2016</b> , 17, 1591-8	2
72	Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. <b>2016</b> , 59, 266-74	64
71	Cardiovascular safety of anti-diabetic drugs. <b>2016</b> , 2, 32-43	34
70	Pancreatic regulation of glucose homeostasis. <b>2016</b> , 48, e219	317
69	Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis. <b>2016</b> , 114, 160-72	11
68	Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. <b>2016</b> , 9, 241-65	16
67	Dapagliflozin combination therapy in type 2 diabetes mellitus. <b>2016</b> , 128, 124-36	2
66	The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide. <b>2016</b> , 32, 61-76	20
65	Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds. <b>2017</b> , 57, 52-63	3
64	Cardiovascular safety and benefits of GLP-1 receptor agonists. <b>2017</b> , 16, 351-363	25
63	Semaglutide: a promising new glucagon-like peptide-1 receptor agonist. <b>2017</b> , 5, 236-238	12
62	The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy. <b>2017</b> , 34, 638-657	3
61	Glucagon-like peptide-1 agonists for weight loss in people with obesity. <b>2017</b> , 5, 29-43	
60	Gastrointestinal-Renal Axis: Role in the Regulation of Blood Pressure. <b>2017</b> , 6,	23
59	Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, 1244-1264	3-5 9
58	WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. <b>2017</b> ,	1
57	Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. <b>2017</b> , 19, 524-536	216

56	Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. <b>2017</b> , 41, 524-535	40
55	Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c $\geq 10.0\%$ : Two pooled analyses including 20 randomised controlled trials. <b>2017</b> , 71, e13029	3
54	Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, 1780-1789.e33	3.5 21
53	Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. <b>2017</b> , 136, 849-870	279
52	Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus. <b>2017</b> , 125, 419-435	6
51	Cardiovascular safety of therapies for type 2 diabetes. <b>2017</b> , 16, 13-25	5
50	Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. <b>2018</b> , 7, 18-23	3
49	Studying the impact on weight and glycaemic control in adults with diabetes attending a group-based commercial weight management programme. <b>2017</b> , 28, 60-66	1
48	Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice. <b>2017</b> , 17, 68	4
47	Comparative effectiveness of glycaemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials. <b>2017</b> , 10, 111-122	19
46	Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data. <b>2018</b> , 34, 1045-1051	1
45	Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. <b>2018</b> , 20, 2121-2130	17
44	Pharmacotherapy of type 2 diabetes: An update. <b>2018</b> , 78, 13-42	103
43	GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. <b>2018</b> , 1864, 2814-2821	60
42	Battle of GLP-1 delivery technologies. <b>2018</b> , 130, 113-130	45
41	Current Antidiabetic Drugs: Review of Their Efficacy and Safety. <b>2018</b> , 455-473	7
40	Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. <b>2019</b> , 10, 1645-1717	17
39	Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study. <b>2019</b> , 10, 73-80	



38	Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency. <b>2019</b> , 16, 2278-2295	27
37	Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output. <b>2019</b> , 41, 73-84	22
36	Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients. <b>2019</b> , 11, 509-518	8
35	Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis. <b>2020</b> , 3, e00100	2
34	Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. <b>2020</b> , 111, 154343	18
33	Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. <b>2020</b> , 18, 322	1
32	Weight-centric pharmacological management of type 2 diabetes mellitus - An essential component of cardiovascular disease prevention. <b>2020</b> , 34, 107619	7
31	Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1. <b>2020</b> , 11, 1077-1090	1
30	Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis. <b>2020</b> , 9, e015323	6
29	Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly. <b>2017</b> , 19, 1793-1797	3
28	Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. <b>2016</b> , 11, e0154206	18
27	A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats. <b>2016</b> , 11, e0154727	7
26	Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists. <b>2009</b> , 6, 247-59	13
25	The role of incretin therapy at different stages of diabetes. <b>2011</b> , 8, 323-38	20
24	Cardiovascular effects of incretin-based therapies. <b>2011</b> , 8, 382-91	15
23	A review of exenatide as adjunctive therapy in patients with type 2 diabetes. <b>2009</b> , 3, 219-40	31
22	Emerging role of GLP-1 receptor agonists in the treatment of obesity. <b>2010</b> , 3, 263-73	8
21	Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. <b>2014</b> , 20, 7356-65	30

20	Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future. <b>2016</b> , 20, 254-67		44
19	Pleiotropic Effects of GLP-1. Cardiovascular Evidence of Effectiveness. <b>2013</b> , 04, 647-650		2
18	Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes. <b>2010</b> , 3, 363-72		2
17	Pharmacological effects and results of clinical trials of the first incretinomimetic exenatide. <b>2011</b> , 14, 63-68		
16	Efficacy of GLP-1 analog to achieve metabolic control and correction of body weight in patients with type 2 diabetes mellitus. <b>2011</b> , 10, 114-119		
15	References, Bibliography & Further Reading. <b>2012</b> , 287-306		
14	Evolution of Biochemical Effects of Byetta <sup>®</sup> in Type 2 Diabetics with Cardiovascular Risk. <b>2013</b> , 04, 679-683		
13	Optimization of Exenatide plus Detemir Treatment for Morbid Obese Patients with Insulin Dependent Diabetes Resistant to Conventional Treatment. Effect of Exenatide on Patients with Mellitus Diabetes Type 2. <b>2014</b> , 05, 433-443		
12	Longitudinal Evaluation and Meta-analysis of Clinical Articles on the Antihypertensive Effects of Incretin-related Drugs. <b>2017</b> , 43, 201-214		1
11	Role and development of GLP-1 receptor agonists in the management of diabetes. <b>2009</b> , 2, 37		2
10	Incretin agents in type 2 diabetes. <b>2010</b> , 56, 639-48		30
9	Alogliptin: a new addition to the class of DPP-4 inhibitors. <b>2009</b> , 2, 117-26		15
8	Diabetes: glycaemic control in type 2 (drug treatments). <i>Clinical Evidence</i> , <b>2012</b> , 2012,		6
7	Cardiovascular safety profile of currently available diabetic drugs. <i>Ochsner Journal</i> , <b>2014</b> , 14, 616-32	1.5	27
6	Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis. <i>EClinicalMedicine</i> , <b>2021</b> , 42, 101213	11.3	5
5	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan <sup>®</sup> 2022 Update. <b>2022</b> ,		8
4	Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis. <b>2022</b> , 100456		0
3	Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis. <b>2022</b> , 11, 7094		0

2 Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome. **2023**, 161, 114561 ○

1 GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. 14, ○